Oruka Therapeutics, Inc. ORKA Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s available-for-sale debt securities - amortized cost?
- Oruka Therapeutics, Inc. (ORKA) reported available-for-sale debt securities - amortized cost of $492.33M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s available-for-sale debt securities - amortized cost changed year-over-year?
- Oruka Therapeutics, Inc.'s available-for-sale debt securities - amortized cost increased by 33.5% year-over-year, from $368.84M to $492.33M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.